SCHEMBL5923002

SCHEMBL5923002

CCCCOc1ccc(NC(=N)Nc2nc(C)cc(C)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.57
▸ TP53 P04637 2/20 0.57
▸ KMT2A Q03164 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ GLA P06280 1/20 0.50
▸ HSD17B10 Q99714 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ LMNA P02545 3/20 0.47
▸ GAA P10253 1/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ POLB P06746 1/20 0.44
▸ PTGES O14684 1/20 0.44
▸ FAAH O00519 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923381 0.97 MAPT (0.55) MAPTTP53KMT2AALDH1A1GLA
SCHEMBL5923063 0.96 MAPT (0.54) MAPTTP53KMT2AALDH1A1GLA
SCHEMBL13310313 0.95 MAPT (0.52) MAPTTP53KMT2AALDH1A1GLA
SCHEMBL5923088 0.89 MAPT (0.48) MAPTTP53KMT2AALDH1A1GLA
SCHEMBL5923110 0.85 S1PR1 (0.46) MAPTTP53ALDH1A1HSD17B10KDM4E
SCHEMBL4983215 0.84 PTGES (0.56) LMNAGAAPTGESFAAHSMN1; SMN2
Bromide SCHEMBL5458791 0.83 PTGES (0.55) LMNAGAAPTGESFAAHSMN1; SMN2
SCHEMBL5923100 0.83 GAA (0.44) MAPTTP53GAAFAAH
SCHEMBL5923283 0.82 MAPT (0.58) MAPTKMT2AALDH1A1KDM4EHPGD
SCHEMBL5923126 0.82 CHRNB2 (0.50) MAPTTP53KMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
WO-2005095345-A2 HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-10-13 — — WO claimed
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-08-04 — — US disclosed
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS AARS1, EPRS1, EEF1G MAPT 1595/4885TP53 3777/4885KMT2A 2096/4885
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication PIGS, GUCY1A1, GUCY1B1 MAPT 2982/4885TP53 2375/4885KMT2A 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback